MetaCap

ACADIA Pharmaceuticals (ACAD) vs Telix Pharmaceuticals (TLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Telix Pharmaceuticals (TLX) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, losing 6.1% versus a loss of 27.4%. ACADIA Pharmaceuticals is the larger company by market cap ($2.96 billion vs $2.84 billion), about 1.0 times the size, while Telix Pharmaceuticals is growing revenue faster (+55.6% vs +11.9%). On valuation, ACADIA Pharmaceuticals trades at a lower trailing P/E (8.1x vs 83.7x for Telix Pharmaceuticals).

ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus -0.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACAD-27.38%TLX-6.06%
+48%+7%-34%
Nov 21, 20251 yearNov 20, 2026
ACAD+2.03%TLX-43.64%
+83%+10%-63%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACAD versus TLX key metrics
MetricACADTLX
Share price$17.11$8.37
Market cap$2.96B$2.84B
1-day change-2.73%-3.90%
YTD return-35.94%+11.75%
1-year return-27.38%-6.06%
5-year return-8.94%—
P/E ratio (TTM)8.0783.70
Forward P/E15.75—
EPS (TTM)$2.12$0.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.07B$803.79M
Revenue growth (YoY)+11.87%+55.61%
Net income (latest FY)$391.00M$-7.13M
Gross margin91.69%53.05%
Operating margin9.78%3.70%
Net margin36.49%-0.89%
52-week high$30.96$13.11
52-week low$15.86$6.28
Distance from 52-week high-44.74%-36.16%
Analyst consensusbuystrong_buy
Avg. price target upside+77.21%+134.89%
Average volume2.18M356.74K
Shares outstanding172.83M339.78M
Employees7961,120
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TLX has outperformed ACAD by 21.3 percentage points over the past year.
  • Telix Pharmaceuticals trades at a higher earnings multiple (83.7x vs 8.1x trailing P/E).
  • ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus -0.9 cents for Telix Pharmaceuticals.
  • Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs +11.87%).

About ACADIA Pharmaceuticals

ACAD stock →

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees

About Telix Pharmaceuticals

TLX stock →

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees

ACAD vs TLX FAQ

Which is bigger, ACADIA Pharmaceuticals or Telix Pharmaceuticals?

ACADIA Pharmaceuticals (ACAD) is larger, with a market capitalization of $2.96B compared with $2.84B for Telix Pharmaceuticals (TLX).

Which stock has performed better over the past year, ACAD or TLX?

TLX returned -6.06% over the past 12 months, compared with -27.38% for ACAD (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ACAD or TLX?

ACAD has the lower trailing P/E at 8.1, versus 83.7 for TLX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are ACADIA Pharmaceuticals and Telix Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons